Talquetamab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany) and SMC (Scotland) recommended or restricted talquetamab, while CIPM (Spain) did not recommend it.
The record spans 2.2 years, opening at G-BA (Germany) on 7 Mar 2024 and running to 8 Jun 2026.
No assessment is on file from HAS (France), PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for talquetamab, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 7 of 7 records date from 2023 or later.
3 distinct indication wordings are recorded for talquetamab by the agencies that label one in English (AWMSG, NICE and SMC).
G-BA (Germany) was first to assess talquetamab, on 7 Mar 2024; NICE (England) did not open a file until 3 Dec 2025 — a moderate spread of 1.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 3 of 7 dated records fall in 2024 alone.
SMC (Scotland) is the only agency to have returned to talquetamab, recording 2 separate entries.
6 of the 18 agencies in this archive hold a record for talquetamab.
The full ledger for talquetamab reads 1 recommended, 1 appraised, 1 deferred to NICE and 1 pending, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NICE (England) | 3 Dec 2025 | NICE TA1114 | published appraisal | source |
| AWMSG (Wales) | 31 Oct 2025 | Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at leas… | excluded, NICE appraised | source |
| CHUIKYO (Japan) | 6 Aug 2025 | タービー: cost-effectiveness evaluation (new product, high price or high sales) | evaluation under way | source |
| SMC (Scotland) | 12 Aug 2024 | As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulat… | not recommended | source |
| CIPM (Spain) | 17 Jul 2024 | Indicación terapéutica autorizada: TALVEY está indicado en monoterapia para el tratamiento de pacientes adultos con miel… | not financed by the SNS · art. 92 d | source |
2 further decisions for talquetamab, across 2 agencies, are not shown here. They include the most recent record on file, 8 Jun 2026 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 2 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 7 decisions for talquetamab from 6 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.